Free Trial

Recursion Pharmaceuticals (RXRX) Competitors

Recursion Pharmaceuticals logo
$5.84 +0.32 (+5.80%)
Closing price 04:00 PM Eastern
Extended Trading
$5.88 +0.04 (+0.68%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

RXRX vs. BPMC, ROIV, ELAN, LEGN, RGC, RVMD, GRFS, TGTX, NUVL, and LNTH

Should you be buying Recursion Pharmaceuticals stock or one of its competitors? The main competitors of Recursion Pharmaceuticals include Blueprint Medicines (BPMC), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), Legend Biotech (LEGN), Regencell Bioscience (RGC), Revolution Medicines (RVMD), Grifols (GRFS), TG Therapeutics (TGTX), Nuvalent (NUVL), and Lantheus (LNTH). These companies are all part of the "pharmaceutical products" industry.

Recursion Pharmaceuticals vs. Its Competitors

Blueprint Medicines (NASDAQ:BPMC) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, media sentiment, earnings, analyst recommendations and profitability.

Blueprint Medicines presently has a consensus target price of $128.25, suggesting a potential downside of 0.95%. Recursion Pharmaceuticals has a consensus target price of $7.00, suggesting a potential upside of 19.86%. Given Recursion Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Recursion Pharmaceuticals is more favorable than Blueprint Medicines.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Blueprint Medicines
0 Sell rating(s)
17 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.24
Recursion Pharmaceuticals
0 Sell rating(s)
4 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

In the previous week, Blueprint Medicines had 7 more articles in the media than Recursion Pharmaceuticals. MarketBeat recorded 8 mentions for Blueprint Medicines and 1 mentions for Recursion Pharmaceuticals. Blueprint Medicines' average media sentiment score of 1.15 beat Recursion Pharmaceuticals' score of 0.81 indicating that Blueprint Medicines is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Blueprint Medicines
4 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Recursion Pharmaceuticals
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

89.1% of Recursion Pharmaceuticals shares are held by institutional investors. 4.2% of Blueprint Medicines shares are held by company insiders. Comparatively, 8.4% of Recursion Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Blueprint Medicines has higher revenue and earnings than Recursion Pharmaceuticals. Blueprint Medicines is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Blueprint Medicines$508.82M16.43-$67.09M-$2.47-52.42
Recursion Pharmaceuticals$58.84M40.35-$463.66M-$1.77-3.30

Blueprint Medicines has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500. Comparatively, Recursion Pharmaceuticals has a beta of 0.91, suggesting that its stock price is 9% less volatile than the S&P 500.

Blueprint Medicines has a net margin of -27.70% compared to Recursion Pharmaceuticals' net margin of -961.32%. Blueprint Medicines' return on equity of -64.60% beat Recursion Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Blueprint Medicines-27.70% -64.60% -17.22%
Recursion Pharmaceuticals -961.32%-74.70%-54.02%

Summary

Blueprint Medicines beats Recursion Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

Get Recursion Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for RXRX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RXRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RXRX vs. The Competition

MetricRecursion PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$2.24B$2.46B$5.54B$9.41B
Dividend YieldN/A1.80%3.75%4.03%
P/E Ratio-3.304.4521.0120.09
Price / Sales40.35709.89433.8199.01
Price / CashN/A164.7736.1658.27
Price / Book2.245.008.125.65
Net Income-$463.66M$30.99M$3.25B$257.91M
7 Day Performance10.61%1.69%0.97%2.09%
1 Month Performance14.29%9.20%7.36%11.13%
1 Year Performance-25.79%-1.25%31.31%18.40%

Recursion Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RXRX
Recursion Pharmaceuticals
1.1335 of 5 stars
$5.84
+5.8%
$7.00
+19.9%
-33.9%$2.24B$58.84M-3.30400Gap Up
High Trading Volume
BPMC
Blueprint Medicines
1.0832 of 5 stars
$129.36
+0.0%
$128.25
-0.9%
+13.2%$8.35B$508.82M-52.36640News Coverage
Positive News
High Trading Volume
ROIV
Roivant Sciences
2.6714 of 5 stars
$11.57
+1.8%
$16.50
+42.7%
+3.6%$7.86B$29.05M-46.26860
ELAN
Elanco Animal Health
1.8068 of 5 stars
$14.88
-0.2%
$15.33
+3.1%
+14.6%$7.40B$4.44B20.149,000Analyst Upgrade
Analyst Revision
LEGN
Legend Biotech
3.5835 of 5 stars
$39.81
+2.2%
$72.70
+82.6%
-23.4%$7.31B$627.24M-67.452,609News Coverage
Positive News
Analyst Forecast
Analyst Revision
RGC
Regencell Bioscience
0.2214 of 5 stars
$14.27
-3.3%
N/AN/A$7.29BN/A0.0010Gap Up
RVMD
Revolution Medicines
4.5503 of 5 stars
$38.76
+1.9%
$68.00
+75.5%
-15.9%$7.20B$11.58M-9.67250Analyst Forecast
GRFS
Grifols
3.8994 of 5 stars
$9.77
+0.3%
$10.30
+5.5%
+24.7%$6.71B$7.81B8.3523,822News Coverage
TGTX
TG Therapeutics
3.4049 of 5 stars
$38.70
+4.3%
$43.80
+13.2%
+77.5%$6.09B$329M159.75290
NUVL
Nuvalent
3.1882 of 5 stars
$83.79
+3.5%
$119.60
+42.7%
+6.4%$6.01BN/A-19.0640Insider Trade
LNTH
Lantheus
4.6282 of 5 stars
$82.30
+1.2%
$131.20
+59.4%
-39.5%$5.70B$1.53B23.41700News Coverage
Positive News
Analyst Forecast

Related Companies and Tools


This page (NASDAQ:RXRX) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners